<DOC>
	<DOCNO>NCT00957359</DOCNO>
	<brief_summary>The primary objective double-blind , placebo-controlled pilot study assess efficacy psilocybin administration ( 4-phosphoryloxy-N , N-dimethyltryptamine ) , serotonergic psychoactive agent , psychosocial distress , specific primary outcome variable anxiety associate cancer . Secondary outcome measure look effect psilocybin symptom pain perception , depression , existential/psychospiritual distress , attitude towards disease progression death , quality life , spiritual/mystical state consciousness . In addition , secondary objective study determine feasibility administer psilocybin patient population , regard follow issue : safety , patient recruitment , consent treatment , retention . The duration propose investigation long enough administer drug one time thirty-two patient conduct follow-up assessment . This study separate similar recently complete study Los Angeles Biomedical Research Institute Harbor-UCLA Medical Center , run psychiatrist , Dr. Charles Grob . Although outcomes measure would similar use Grob study , propose dose psilocybin high 0.3mg/kg total subject study would 32 instead 12 . The study utilizes cross-over design 7 week include prospective follow-up 6 month duration . This study approve Bellevue Psychiatry Research Committee , NYU Oncology PRMC Committee , Food Drug Administration ( FDA ) issuance IND ( 77,138 ) , New York University School Medicine Institutional Review Board ( NYU IRB ) , Health Hospitals Corporation ( HHC ) -New York University ( NYU ) Clinical Translational Science Institute ( CTSI ) , NYU Bluestone Center Clinical Research , Drug Enforcement Agency ( DEA ) issuance schedule I license . It hypothesize one time experience psilocybin occasion dramatic shift consciousness awareness lead short-term ( ie hour day ) long-term ( 6 month study , follow administration second dosing , either psilocybin placebo ) improvement anxiety , depression , pain associate advanced cancer . The exact mechanism action unclear base study do 60 's use serotonergic hallucinogen patient advanced cancer , improvement anxiety level , mood pain report . However , treatment model develop famous British psychiatrist Humphrey Osmond , offer one possibility . In model , serotonergic hallucinogen ' therapeutic mechanism lie ability allow individual access novel dimension consciousness efficacy lack thereof rely whether transcendent mystical state awareness attain . Another possible mechanism relate Dobkin de Rios Grob describe 'managed altered state consciousness , ' power suggestibility , occur safe setting , allow one transcend particular state consciousness ( i.e . anxiety depression associate advanced illness ) mean facilitate emotional discharge manage irreconcilable conflict .</brief_summary>
	<brief_title>Psilocybin Cancer Anxiety Study</brief_title>
	<detailed_description />
	<mesh_term>Psilocybine</mesh_term>
	<mesh_term>N , N-Dimethyltryptamine</mesh_term>
	<mesh_term>Hallucinogens</mesh_term>
	<criteria>Age : 1876 Current historical diagnosis cancer Projected life expectancy least one year DSMIV diagnose : Acute Stress Disorder , Generalized Anxiety Disorder , Anxiety Disorder due cancer , Adjustment Disorder anxious feature Any stage cancer diagnosis Epilepsy Renal disease Diabetes Abnormal liver function Severe cardiovascular disease Malignant Hypertension Baseline blood pressure must less equal 140/90 Personal history immediate family member schizophrenia , bipolar affective disorder , delusional disorder , schizoaffective disorder psychotic spectrum illness Current substance use disorder Medication contraindication : antiseizures medication , insulin , oral hypoglycemics , clonidine , aldomet , cardiovascular medication , antipsychotic ( first second generation ) , antidepressant mood stabilizer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Depression</keyword>
	<keyword>Hallucinogens</keyword>
</DOC>